SUMMIT Trial: Tirzepatide Reduces Heart Failure Risk in Obese Patients with HFpEF

SUMMIT Trial: Tirzepatide Reduces Heart Failure Risk in Obese Patients with HFpEF

November 17, 2024 Catherine Williams Health

Research Highlights:

  • The SUMMIT trial involved 713 adults with heart failure with preserved ejection fraction (obesity-related-heart-failure/” title=”Tirzepatide Revolutionizes GLP-1 Medications for Obesity-Related Heart Failure”>HFpEF) and obesity across nine countries, including the U.S. Participants taking tirzepatide for about 2 years had a lower risk of worsening heart failure and cardiovascular death compared to a placebo group.

  • This study is the first to assess a medication’s effects on major heart failure outcomes in individuals with HFpEF and obesity.

  • Tirzepatide is an FDA-approved medication for Type 2 diabetes and chronic weight management. It functions as a receptor agonist for glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1).

  • Updated data and statistics will be available in the full manuscript published in The New England Journal of Medicine.

Trial Details:

  • The SUMMIT trial evaluated 731 adults aged 40 and older diagnosed with HFpEF and obesity from health centers in nine countries. All participants had an ejection fraction of 50% or more and a BMI of 30 kg/m² or higher.

  • Participants were randomly assigned to receive either tirzepatide or a placebo in a double-blind manner. Over their participation, doses of tirzepatide increased from 2.5 mg to a maximum of 15 mg weekly.

Key Findings:

  • The trial recorded 36 cardiovascular deaths or worsening heart failure events (9.9%) in the tirzepatide group and 56 (15.3%) in the placebo group, indicating a 38% risk reduction in the tirzepatide group.

  • Worsening heart failure events occurred in 29 patients (8.0%) in the tirzepatide group versus 52 (14.2%) in the placebo group, showing a 46% risk reduction.

  • KCCQ-CSS scores improved by an average of 6.9 points more in the tirzepatide group, reflecting better health status and function.

  • Participants in the tirzepatide group experienced 11.9% greater weight loss and improved their six-minute walk distance by an average of 18.3 meters compared to the placebo group.

  • A significant reduction in inflammation was observed in the tirzepatide group, with a 32.9% decrease in high-sensitivity C-reactive protein levels compared to placebo.

Conclusion:

These results indicate that tirzepatide provides meaningful benefits for people with HFpEF and obesity. Participants reported lower risks of worsening heart failure and cardiovascular death, alongside improved health and exercise capability. This study marks the first finding that a medication can positively impact the clinical course of these patients.

Study Parameters:

  • The trial ran from April 2021 to June 2023, screening 1,494 patients and enrolling 731 participants, with an average age of 65.2 years and a mean BMI of 38.3 kg/m².

  • The trial monitored weight, heart failure symptoms, and treatment side effects regularly.

  • Approximately 4% in the tirzepatide group discontinued due to gastrointestinal symptoms.

This trial suggests potential new avenues for treating HFpEF in patients with obesity, emphasizing further research to clarify ideal treatment candidates.

,